AI Drug Discovery Firm Isomorphic Labs in Early Talks for Funding at $40B-$50B Valuation

Bloomberg reported on Oct. 8 that Isomorphic Labs, Alphabet's AI-powered drug discovery company, is in early talks for a new funding round. The company is seeking a valuation of at least $40 billion, which could reach $50 billion, according to sources.

Led by Demis Hassabis, the 2024 Nobel Prize laureate in chemistry, Isomorphic Labs focuses on applying artificial intelligence to accelerate drug discovery. The company completed a Series B round in May 2026, raising $2.1 billion from its parent company and other investors.

The report noted that the application of AI in biopharmaceuticals remains in its early stages. While several players have explored the concept, significant efforts are still needed before such approaches can move through clinical trials and ultimately reach the market.